期刊文献+

液相色谱质谱联用检测血液和尿液中的琥珀胆碱及对标样的稳定性评价 被引量:7

Determination of succinycholine in the urine and plasma by LC/MS and stability evaluation of the reference materials
原文传递
导出
摘要 采用OasisR WCX固相萃取柱,用50%甲醇溶液洗脱杂质,并用1 mL甲酸-乙腈-水(1∶8∶1)溶液进行淋洗目标物。采用LC/MS/ESI检测其母离子为145.1,并选择115.5作为其定量离子。在尿液和血液中进行了回收率实验,测得其定量检测限分别为0.92ng/mL,1.89ng/mL(10倍S/N),方法的线性范围均在0.02~100μg/mL。并对标准物品在储存介质中的稳定性做了统计检验,测得10 d之内,1μg/mL琥珀胆碱标准样品在塑料容器中未检测到不稳定,储存稳定,而在玻璃容器中其降解几乎达90%。 The pretreatment process for succinycholine was as follows:using Oasis○R WCX as a SPE column(The sorbent is suitable for the extraction of the quaternary ammounium salts),employing 50% methanol water solution to elute impurity,and using 1mL of 10% formic acid-80% acetonitrile water solution to elute the target compound.Because succinycholine has two positive charges,the ion at m/z =145.1 as the parent ion and the ion at m/z =115.5 for the quantitative ion were determined by LC/MS(ESI).The method was evaluated by calculating the recovery with adding different amounts of succinycholine in the urine and blood.The experimental results showed that the limits of quantitation were 0.92 ng/mL in urine and 1.89 ng/mL in blood,respectively(at a signal to noise ratio of 10),and the linear ranges in different matrixes were all between 0.02 μg/mLand 100 μg/mL.In the work,we also made the static evaluation for the reference materials by depositing 1μg/mL succinycholine in different mediums and measuring the respective responses during 10 days.The results showed that succinycholine was stable in the plastic,and it degradated obviously in the glass with degression of almost 90%.
出处 《分析试验室》 CAS CSCD 北大核心 2011年第8期112-114,共3页 Chinese Journal of Analysis Laboratory
关键词 琥珀胆碱 液相色谱质谱 尿液 血液 稳定性评价 Succinycholine High performance liquid chromatography electrospray ionization tandem mass spectrometry Urine Plasma Stability evaluation
  • 相关文献

参考文献3

二级参考文献25

  • 1Sluga M, Ummenhofer W, Studer W, et al. Rocuronium versus succinylcholine for rapid sequence induction of anesthesia and endotraeheal intubation: a prospective, randomized trial in emergent cases. Anesth Analg, 2005, 101, 1356-1361.
  • 2Naguib M, Lien C A. Chapter 13: Pharmacology of muscle relaxants and their antagonists//Miller R D. Anesthesia. 6th ed. Philadelphia:Elsevier Churchill Livingstone, 2005: 481- 572.
  • 3Martyn J A, Richtsfeld M. Succinylcholine-induced hyperka-lemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology, 2006, 104; 158-169.
  • 4Jonsson M, Dabrowski M, Gurley D A, et al. Activation and inhibition of human muscular and neuronal nicotinic acetylcholine receptors by succinylcholine. Anesthesiology, 2006, 104: 724-733.
  • 5Martyn J A J. Chapter 22.. Neuromuscular physiology and pharmacology//Miller R D. Anesthesia. 6th ed. Philadelphia : Elsevier Churchill Livingstone, 2005 : 859-879.
  • 6Garcia N, Santafe M M, Salon I, et al. Expression of muscarinic acetylcholine receptors (M1-, M2-, M3- and M4- type) in the neuromuscular junction of the newborn and adult rat. HistolHistopathol, 2005, 20: 733-743.
  • 7Naguib M. Are fade and sustained post-tetanic facilitation characteristics of typical sueeinyleholine-induced block. Br J Anaesth, 2001, 87: 522-524.
  • 8Naguib M, Samarkandi A, Riad W, et al. Optimal dose of suceinyteholine revisited. Anesthesiology, 2003, 99: 1045- 1049.
  • 9Naguib M, Lien C A, Aker J, et al. Posttetanie potentiation and fade in the response to tetanie and train-of-four stimulation during succinylcholine-indueed block. Anesth Analg, 2004, 98:1686-1691.
  • 10El-OrbanyMI, Joseph N J, Salem M R, et al. The neuromuscular effects and tracheal intubation conditions after small doses of succinylcholine. Anesth Analg, 2004, 98: 1680-1685.

共引文献13

同被引文献65

  • 1Office of British 2013:0248. Office of Europe 2010:3028-3029.
  • 2Pharmacoeia Commision. BP2013[S] Pharmacoeia Commision. EUP7.0[S].
  • 3Chen S, Soneji V, Webster J. Determination of choline in pharmaceutical formulations by reversed-phase high- performance liquid chromatography and postcolumn suppression conductivity detection[J]. J Chromatogr A, 1996,739(1-2) :351-357.
  • 4The United States Pharmacopeial Convention. USPM onographs : Succinylcholine Chloride. USP29-NF24 IS]. 2006 : 4692-4694.
  • 5李双斌,梁永民,蒋琦,等.正相硅胶反相洗脱色谱法测定氯化琥珀胆碱的含量[C]//2009年药物分析会议论文汇总.2009:49-57.
  • 6Kuepper U, Musshoff F, Madea B. A fully validat- ed isotope dilution HPLC-MS/MS method for the si- multaneous determination of succinylcholine and suc- cinylmonocholine in serum and urine samples[J]. J Mass Spectrom, 2008,43 (10) : 1344-1352.
  • 7Ho EN, Kwok WH, Wong AS, et d. Detection of singly- and doubly-charged quaternary ammonium drugs in equine urine by liquid chromatography/tan- dem mass spectrometry[J]. Anal Chim Acta,2012, 710:94-101.
  • 8孙士青,史建国,李雪梅,杨俊慧,马跃宏,孟庆军,张立群,杨艳,王丙莲,赵晓华.酶电极法测定氯化琥珀胆碱注射液中氯化胆碱含量[J].山东科学,2007,20(6):22-24. 被引量:3
  • 9RUIYC(芮耀诚).现代药物学[M].北京:人民军医出版社,1999:273.
  • 10GA58-93.剧毒物品品名表[S].2008:9.

引证文献7

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部